Analyst Price Targets — BEAM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 21, 2026 10:39 am | Patrick Trucchio | H.C. Wainwright | $80.00 | $27.11 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM) |
| May 13, 2026 10:27 am | William Pickering | Tudor Pickering | $39.00 | $31.58 | TheFly | Beam Therapeutics price target lowered to $39 from $40 at Bernstein |
| February 25, 2026 2:20 pm | — | RBC Capital | $26.00 | $30.83 | TheFly | Beam Therapeutics price target raised to $26 from $22 at RBC Capital |
| February 20, 2026 11:29 am | — | Canaccord Genuity | $74.00 | $27.88 | TheFly | Beam Therapeutics initiated with a Buy at Canaccord |
| January 21, 2026 12:44 pm | William Pickering | Tudor Pickering | $41.00 | $31.00 | StreetInsider | Beam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update |
| January 20, 2026 11:44 pm | — | Bernstein | $41.00 | $30.97 | TheFly | Beam Therapeutics price target raised to $41 from $37 at Bernstein |
| January 7, 2026 5:40 am | Michael Yee | UBS | $28.00 | $28.34 | StreetInsider | UBS Starts Beam Therapeutics Inc (BEAM) at Neutral |
| November 24, 2025 1:11 pm | — | Evercore ISI | $35.00 | $23.32 | TheFly | Beam Therapeutics initiated with an Outperform at Evercore ISI |
| October 9, 2025 3:43 pm | — | Jefferies | $41.00 | $27.86 | TheFly | Beam Therapeutics initiated with a Buy at Jefferies |
| May 7, 2025 12:18 pm | Debjit Chattopadhyay | Guggenheim | $55.00 | $15.99 | TheFly | Beam Therapeutics price target lowered to $55 from $78 at Guggenheim |
Latest News for BEAM
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in…
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BEAM.
U.S. House Trading
No House trades found for BEAM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.